1Bohax A J, Fischel E E. Serologic tests for inflammation; serum com- plement, c-reactive protein and erythrocyte sedimentation rate in myo-cardial infarction [ J]. Am J Med, 1956, 20 (3) : 418-427.
2Kroop I G, Sbaekman N H. Level of C-reactive protein as a measure of acute myocardial infarction[ J]. Proc Soc Exp Biol Med, 1954, 86 (1): 95-97.
3Suzuki M. Acute coronary syndromes as auto-inflammatory disorders [J]. CurrPharm Des, 2012, 18(28): 4370-4384.
4Biasucci L M, Liuzzo G, Angiolillo D J, et al. Inflammation and a- cute coronary syndromes [ J]. Herz, 2000, 25 (2) : 108-112.
5Cheng X, Liao Y H, Ge H, et al. TH1/TH2 functional imbalance af- ter acute myocardial infarction : coronary arterial inflammation or myo- cardial inflammation[J]. J Clin Immunol, 2005, 25(3) : 246-253.
6Kilbottrn R G, Traber D L, Szabo C. Nitric oxide and shock[J]. Dis Mon, 1997, 43(5) : 277-348.
7Reynolds H R, Hochman J S. Cardiogenic shock: current concepts and improving outcomes[ J]. Circulation, 2008, 117 (5) : 686-697.
8Howes L G, Brillante D G. Expert opinion on tilarginine in the treat- ment of shock [ J]. Expert Opin Investig Drugs, 2008, 17 (10) : 1573-1580.
9Kaluski E, Uriel N, Milo-Cotter O, et al. Nitric oxide synthase in- hibitors in cardiogenic shock: present and future[J]. Future Cardiol, 2008, 4(2) : 183-189.
10Alexander J H, Reynolds H R, Stebbins A L, et al. Effect of tilargin- ine acetate in patients with acute myocardial infarction and cardiogenic shock: the TRIUMPH randomized controlled trial[ J]. JAMA, 2007, 297(15) : 1657-1666.
8JONES P, KAFONEK S, LAURORA I, et al. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia ( the CURVES study ) [ J 1. Am J Cardiol, 1998,81 (5) : 582-587.
9LI T, WANG D,TIAN Y, et al.Effects of atorvastatin on the inflammation regulation and elimination of subdural hematoma in rats[ J ] .J Neurol Sci ,2014,341 (1/2) :88-96.
